GMP Drug Inc., a wholly-owned subsidiary of Core One Labs Inc. (OTCQB:CLABF) (CSE:COOL)(Frankfurt:LD6) (WKN: A3CSSU) has entered into a non-binding letter of intent with Zollaris Laboratories Corporation, an arms-length party, in pursuit of a potential transaction involving the sale by GMP Drug of psychedelic compounds including but not limited to biosynthetic psilocybin, psilocin, DMT formulated by Vocan Biotechnologies Inc. and Awakened Biosciences Inc., each also wholly-owned subsidiaries of Core One.
Zollaris is a licensed pharmaceutical company that currently holds a license to possess, and conduct laboratory analysis on, psilocybin. The LOI proposes that GMP Drug will enter an arrangement in which Awakened and Vocan will formulate and GMP Drug will supply proprietary psychedelics produced using the patent-pending production methods of Awakened and Vocan, to Zollaris, pursuant to a definitive agreement, the terms of which are currently under negotiation. It is anticipated that the proprietary psychedelic compounds will be supplied to Zollaris at an agreed upon cost per gram, and in amounts requested by Zollaris.
The definitive agreement is anticipated to incorporate the principal terms set forth in the LOI and, in addition, such other terms and provisions of a more detailed nature as the parties may agree upon and as are customary for transactions of this nature. The consummation of the final supply arrangement is subject to a number of conditions, including the satisfaction of each party's respective due diligence, the negotiation and execution of the definitive agreement and Zollaris holding a valid controlled substances license from Health Canada permitting the acquisition and possession of psilocybin.
Photo: Benzinga edit with photos by geralt and sergeitokmakov on Pixabay
Benzinga Cannabis Capital Conference
The Benzinga Cannabis Capital Conference, the place where deals get done, is returning to Chicago this Sept 27-28 for its 17th edition. Get your tickets today before prices increase and secure a spot at the epicenter of cannabis investment and branding.
Related News
Core One In Talks With Multiple Companies To Supply Psilocybin
